Hair Foundation Blog

At the recent 2012 Winter Clinical Dermatology Conference in Maui, the Hair Foundation’s Vice Chair, Dr. Ken Washenik, M.D, Ph.D., gave a presentation called, “Emerging Therapies for Hair Loss.”  It focused on new and breakthrough treatments in hair loss, such as clinical treatments.

Another topic in Washenik’s discussion was the progress Aderans Research has made on the Ji Gami™ family of cell products. This is a key component in the company’s cell-based solutions to androgenetic alopecia (pattern hair loss), according to a press release.

Washenik serves as the company’s chief executive. Earlier this month, Aderans Research announced the expansion of its hair loss clinical trials to four new cities. With almost 350 subjects, this trial represents one of the largest for researching cell-based solutions for pattern hair loss.

Aderans Research has been a pioneer in the research and development of safe, effective cell engineered products for hair regeneration. The Atlanta-based company is a subsidiary of Aderans Co., Ltd, the world’s largest wig manufacturer, and an affiliate of Bosley, a global leader in surgical hair restoration.

In addition to his presentation on hair loss, Washenik was also a participant in an audience question and answer session comprised of practicing dermatologists.

Joining Washenik at the conference were two other Hair Foundation members. The doctors sat on the following panels.

Hair Foundation Scientific Advisory Council Member Dr. Valerie Callender, M.D

Clinical and Therapeutic Challenges in Medical Dermatology: Sweat, Hair, Pigmentary Disorders and Warts and Management of Pigment Disorders

Hair Foundation’s Board of Trustees secretary Dr. Zoe Diana Draelos,  M.D., FAAD

Cosmeceuticals in Dermatology and Clinical and Therapeutic Challenges in Appearance Procedures

Tags: Dr. Ken Washenik, Dr. Valerie Callender, Dr. Zoe Diana Draelos

This entry was posted on Thursday, January 26th, 2012 at 8:33 pm and is filed under Conferences, Hair Loss. You can follow any responses to this entry through the RSS 2.0 feed. You can skip to the end and leave a response. Pinging is currently not allowed.